NOVATO

Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones

Retrieved on: 
Friday, January 6, 2023
Acquisition, Osteogenesis imperfecta, Patient, Ageing, OI, Sale, Investment, Pharmaceutical industry, Ultragenyx, Burosumab

NOVATO, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported preliminary unaudited 2022 revenue results, cash and investments at year end 2022, and provided 2023 guidance on select key financial metrics including net cash used in operations.

Key Points: 
  • Cash, cash equivalents, and available-for-sale investments were approximately $900 million as of December 31, 2022.
  • In 2023 with increased focus on key pipeline value drivers, net cash use is projected to be meaningfully reduced.
  • The 2022 revenues and cash position included in this release are preliminary and are therefore subject to adjustment.
  • The preliminary revenue results are based on management’s initial analysis of operations for the year ended December 31, 2022.

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 4, 2023
Conference, Webcast, Pharmaceutical industry, Broadcasting

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 12:45 PM ET.

Key Points: 
  • NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 12:45 PM ET.
  • The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations .
  • The replay of the webcast will be available for 30 days.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, December 21, 2022
Employment, Pharmaceutical industry, Security (finance)

The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2022, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2022, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
  • The stock options vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date and the remainder vesting with respect to 1/48th of the shares underlying the options on each monthly anniversary thereafter, subject to the employee being continuously employed by the company as of such vesting dates.
  • The stock options have a ten-year term and an exercise price of $45.63 per share, equal to the per share closing price of Ultragenyx’s common stock on December 16, 2022.

Allegro MedSpa of Santa Rosa, CA One of the First Practices to Offer DAXXIFY™

Retrieved on: 
Wednesday, December 7, 2022
PXT, Skin, Entrepreneurship, Facial muscles, Patient, Botulinum toxin, FDA, Eyebrow, ROSA, Medical device

SANTA ROSA, Calif., Dec. 7, 2022 /PRNewswire/ -- The founders of Allegro MedSpa, located in Santa Rosa, CA, announces they will offer DAXXIFY, a longer-lasting neuromodulator, starting on December 12, 2022 at both the Santa Rosa and Novato offices.

Key Points: 
  • SANTA ROSA, Calif., Dec. 7, 2022 /PRNewswire/ -- The founders of Allegro MedSpa, located in Santa Rosa, CA, announces they will offer DAXXIFY , a longer-lasting neuromodulator, starting on December 12, 2022 at both the Santa Rosa and Novato offices.
  • "Patients in Northern California and beyond come to Allegro MedSpa to receive the safest, most natural-looking anti-aging results possible."
  • Revance Aesthetics is initially releasing DAXXIFY to only the top 1% of neuromodulator injecting practices nationwide, making Allegro MedSpa one of only six Northern California practices to offer DAXXIFY ahead of its official release in summer 2023.
  • Allegro MedSpa of Santa Rosa is located at 4625 Quigg Dr #1, Santa Rosa, CA 95409.

Ultragenyx to Present at Piper Sandler Healthcare Conference

Retrieved on: 
Tuesday, November 22, 2022
Therapy, Disease, Webcast, Patient, Biology, Conference, Pharmaceutical industry, Ultragenyx

The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .

Key Points: 
  • The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .
  • Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.
  • For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, November 18, 2022
Therapy, Disease, Employment, Patient, Biology, Pharmaceutical industry, Ultragenyx

The awards were approved by the compensation committee of the companys board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2022, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The awards were approved by the compensation committee of the companys board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2022, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.
  • For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .

Ultragenyx Announces Departure of Chief Financial Officer

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Disclosure, Biology, Strategic management, SEC, NASDAQ, Regulation Fair Disclosure, Senior, CFO, Disease, Patient, Social media, Therapy, Security (finance), Regulation, Management, Pharmaceutical industry, Ultragenyx

NOVATO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN, INC. Ted Huizenga, Chief Accounting Officer, and Aaron Olsen, Senior Vice President of Corporate Strategy and Finance, will lead ongoing finance activities during the search for a successor.

Key Points: 
  • NOVATO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the company, effective November 15, 2022, to assume the dual role of CFO and Chief Business Development Officer at privately held ACELYRIN, INC. Ted Huizenga, Chief Accounting Officer, and Aaron Olsen, Senior Vice President of Corporate Strategy and Finance, will lead ongoing finance activities during the search for a successor.
  • Mardi has been a valuable partner over the past two-plus years, helping me to ensure we are well capitalized with a foundation of fiscal responsibility as we head into 2023, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
  • Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases.
  • Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyxs investor relations website ( https://ir.ultragenyx.com/ ) and LinkedIn website ( https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/mycompany/ ).

Ultragenyx to Present at Upcoming Healthcare Conferences

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Conference, Webcast, NASDAQ, Patient, Biology, Therapy, Disease, Pharmaceutical industry, Ultragenyx

The replay of the webcast will be available for 90 days.

Key Points: 
  • The replay of the webcast will be available for 90 days.
  • Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.
  • For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .

Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update

Retrieved on: 
Wednesday, November 2, 2022
Adult, Acquisition, Partnership, Osteomalacia, Șaeș, Program, PMD, KKC, Technology, Osteogenesis imperfecta, FDA, Neoplasm, Communication, Hypophosphatemia, Patient, OI, Ageing, Angelman syndrome, Pharmaceutical industry, Burosumab, Ultragenyx

NOVATO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2022 and provided a corporate update for the year.

Key Points: 
  • During this period, Ultragenyx will continue to share costs of the Crysvita commercial operating expenses with KKC.
  • Ultragenyx will host a conference call today, Wednesday, November 2, 2022, at 2 p.m. PT/ 5 p.m.
  • ET to discuss the third quarter 2022 financial results and provide a corporate update.
  • Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyxs Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/mycompany/).

Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update

Retrieved on: 
Thursday, October 27, 2022
Therapy, Biology, GLOBE, NASDAQ, Disease, Patient, Pharmaceutical industry, Online shopping, Ultragenyx

NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Wednesday, November 2, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2022.

Key Points: 
  • NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Wednesday, November 2, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended September 30, 2022.
  • The live and replayed webcast of the call will be available through the companys website at https://ir.ultragenyx.com/events-presentations .
  • To participate in the live call, please register by clicking on the following link ( registration link ), and you will be provided with dial-in details.
  • Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases.